Brought to you by 
Gilead licenses Japan Tobacco's HIV integrase inhibitor
Mar 2005
Executive Summary
Gilead Sciences (drugs for infectious diseases) has licensed exclusive worldwide rights outside of Japan to develop and sell Japan Tobacco's HIV integrase inhibitor JTK-303.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead licenses Japan Tobacco's HIV integrase inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice